Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

Posted on 15 November 2018 | Posted by John Chapman | Posted in Videos, American Heart Association Scientific Sessions 2018

Lipoprotein(a) was a key focus. First, the 2018 US Cholesterol Guidelines incorporated elevated lipoprotein(a) as a marker of cardiovascular risk. Second, a Latebreaker session showed a favourable benefit versus risk profile for a novel antisense oligonucleotide specific to the apolipoprotein(a) component of lipoprotein(a).

Now the stage is truly set to test the ‘lipoprotein(a) hypothesis’ with a phase III trial to evaluate whether lowering elevated lipoprotein(a) levels reduces cardiovascular events.

Related videos

PlayAHA/ACC 2018 Cholesterol Guidelines also have good points
AHA/ACC 2018 Cholesterol Guidelines also have good points
PlayCoronary artery calcium for stratifying risk in familial hypercholesterolaemia
Coronary artery calcium for stratifying risk in familial hypercholesterolaemia
PlayPCSK9 Forum Inhibitors and Health Economics
PCSK9 Forum Inhibitors and Health Economics
PlayVIDEO: Perspective on the ODYSSEY OUTCOMES Economic Study
Gregory G. Schwartz VIDEO: Perspective on the ODYSSEY OUTCOMES Economic Study

« Back to videos